ContraVir (CTRV) is a development stage company with two targeted antiviral therapies in late-stage clinical trials. The first is CMX157 for hepatitis-B (HBV). CMX157 is a highly potent analog of Gilead’s (GILD) successful antiviral drug tenofovir DF (Viread). In-vitro CMX157 has shown a potency HBV that is ~60x Viread’s potency, and in 2014 Viread (which is indicated for both HIV and HBV) sold over $1B worldwide ($484M in the US). HBV is one of the most under-diagnosed & under-treated indications in the world, with estimates ranging to 300M-400M patients worldwide, and we believe there is plenty of room for multiple agents being used singly and in combination to treat this disease. ContraVir’s second late stage candidate is FV-100 which is being developed for the treatment of herpes zoster (HZV), or shingles, and shingle pain (PHN). Shingles & PHN impacts ~1M people in the US alone and FV-100 could be the first anti-viral to treat both the lesions and the associated pain for HZV.